Opioid Zehirlenmeleri
Özet
Opioidler ve opiatlar, şiddetli ağrı kontrolünde yaygın olarak kullanılan; doğal, yarı sentetik ve sentetik türleri bulunan yüksek suistimal ve bağımlılık potansiyeline sahip ilaç sınıfıdır. Vücutta mukoza organlarından hızla emilerek beyin ve bağırsaktaki Mu, Kappa, Delta ve Sigma nöronal reseptörlerine bağlanırlar. Mu reseptör aktivasyonu analjezi, öfori, bradikardi ve zehirlenmelerdeki temel morbidite ile mortalite nedeni olan solunum depresyonuna yol açar; Kappa ve Sigma reseptörleri ise halüsinasyon, disfori, miyozis ve psikoza neden olur. Karaciğer bozukluğu olanlarda veya CYP2D6 ultra hızlı metabolize edicilerde toksisite riski artmaktadır. Opioid zehirlenmesinin karakteristik klinik üçlüsü; merkezi sinir sistemi depresyonu, solunum depresyonu ve miyozistir. Tanı öncelikle fizik muayene ve anamneze dayanmakta olup, idrar ilaç düzeyi tayininin klinik yönetimi değiştirme değeri kısıtlıdır. Tedavide ilk ve en kritik adım agresif hava yolu kontrolü ile yeterli oksijenizasyonun sağlanmasıdır. Spesifik opioid antagonisti naloksan; intravenöz, intramüsküler veya intranazal yolla uygulanarak solunum ve zihinsel depresyonu geri döndürür. Oral alımlarda hava yolu emniyete alındıktan sonra aktif kömürle dekontaminasyon yapılabilir. Naloksanın yarılanma ömrü çoğu opioidden kısa olduğu için hastalar en az 12-24 saat kardiyorespiratuar izlem altında tutulmalıdır. Süreçte akut akciğer hasarı, enfektif endokardit, nöbet, rabdomiyoliz ve yoksunluk sendromu gibi ciddi komplikasyonlar gözlenebilir.
Opioids and opiates are a class of drugs widely used for severe pain management with high potential for abuse and addiction, comprising natural, semi-synthetic, and synthetic forms. Rapidly absorbed through mucosal membranes, they bind to Mu, Kappa, Delta, and Sigma neuronal receptors in the brain and intestines. Mu receptor activation leads to analgesia, euphoria, bradycardia, and respiratory depression—the primary cause of morbidity and mortality in toxicity—whereas Kappa and Sigma receptors cause hallucinations, dysphoria, miosis, and psychosis. Toxicity risk increases in patients with hepatic impairment or CYP2D6 ultra-rapid metabolizers. The characteristic clinical triad of opioid toxicity consists of central nervous system depression, respiratory depression, and miosis. Diagnosis relies primarily on physical examination and history, while measuring urine drug levels has limited value for changing clinical management. The initial and most critical step in treatment is securing aggressive airway control and ensuring adequate oxygenation. The specific opioid antagonist naloxone is administered via intravenous, intramuscular, or intranasal routes to reverse respiratory and mental depression. Decontamination with activated charcoal can be performed following oral ingestion once the airway is secured. Because naloxone has a shorter half-life than most opioids, patients must be kept under cardiorespiratory monitoring for at least 12 to 24 hours. Serious complications such as acute lung injury, infective endocarditis, seizures, rhabdomyolysis, and withdrawal syndrome may occur during the process.
Referanslar
Blondell RD, Azadfard M, Wisniewski AM. Pharmacologic therapy for acute pain. Am Fam Physician. 2013 Jun 01;87(11):766-72.
Özden, SY. (2004). Uyuşturucu Madde Bağımlılığı. İstanbul: Nobel Tıp Kitapevleri.
Lalic S, Jokanovic N, Ilomäki J, Gisev N, Lloyd B, Lubman DI, Bell JS. Harms associated with extramedical use of prescription opioid analgesics in Australia: A scoping review. Res Social Adm Pharm. 2019 Aug;15(8):925- 935.
Rzasa Lynn R, Galinkin JL. Naloxone dosage for opioid reversal: current evidence and clinical implications. Ther Adv Drug Saf. 2018 Jan;9(1):63-88.
Sadock, B. J., Kaplan, H. I., & Sadock, V. A. (2007). Kaplan & Sadock's synopsis of psychiatry: Behavioral sciences/clinical psychiatry (10th ed.). Philadelphia: Wolter Kluwer/Lippincott Williams & Wilkins.
LaForge KS, Yuferov V, Kreek MJ. Opioid receptor and peptide gene polymorphisms: potential implications for addictions. Eur J Pharmacol. 2000 Dec 27;410(2-3):249-268.
Kreek MJ, Bart G, Lilly C, LaForge KS, Nielsen DA. Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev. 2005 Mar;57(1):1-26.
Tejada M. A., Montilla-García A., Sánchez-Fernández C., Entrena J. M., Perazzoli G., Baeyens J. M., et al. (2014).Sigma-1 receptor inhibition reverses acute inflammatory hyperalgesia in mice: role of peripheral sigma-1 receptors.Psychopharmacology (Berl)231(19), 3855–3869. 10.1007/s00213-014-3524-3
MacKenzie M, Zed PJ, Ensom MHH. Opioid pharmacokineticspharmacodynamics: clinical implications in acute pain Management in Trauma. Annals of pharmacology. 2016;50(3):209–18.
Dean L, Pratt V, McLeod H, Dean L, Malheiro A, Rubinstein W. Codeine Therapy and CYP2D6 Genotype. March 16, 2017.
Miotto K, Cho AK, Khalil MA, Blanco K, Sasaki JD, Rawson R. Trends in Tramadol: Pharmacology, Metabolism, and Misuse. Anesth Analg. 2017 Jan. 124 (1):44-51.
Owusu Obeng A., Hamadeh I., Smith M. Review of Opioid Pharmacogenetics and Considerations for Pain Management. Pharmacother. J. Hum. Pharmacol. Drug Ther. 2017;37:1105–1121. doi: 10.1002/phar.1986
Fareed A, Stout S, Casarella J, et al. Illicit opioid intoxication: diagnosis and treatment. Subst Abus. 2011;5:17–25.
Byard RW, Gilbert JD. Narcotic administration and stenosing lesions of the upper airway a potentially lethal combination. J Clin Forensic Med. 2005 Feb. 12(1):29-31
Boyer EW (2012) Management of opioid analgesic overdose. N Engl J Med 367: 146-55.
Journal of Medicine. Massachussetts Medical Society; 2012. p. 146–55.
Everett Stephens, MD; Chief Editor: Jeter (Jay) Pritchard Taylor, III, MD, Opioid Toxicity Updated: Jun 06, 2020, emedicine.medscape.com
Rıtter JM, Lewis LD, Mant T, Ferro A (2008) Drugs and Alcohol Abuse. A Text Book of Clinical Pharmacology and Theropeutics. Fifth edition. London, s. 433-443.
Tintinalli’s Emergency Medicine: A Comprehensive Study Guide, 8th Edition. McGraw-Hill Education / Medical; 2016.
Kerr D, Kelly AM, Dietze P, Jolley D, Barger B. Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose. Addiction. 2009 Dec. 104(12):2067-74.
Narcan Nasal Spray (naloxone ntranasal) [package nsert]. Radnor, PA: Adapt Pharma, Inc. November, 2015.
FDA News Release. FDA moves quckly to approve easy-to-use nasal spray to treat opod overdose. U.S. Food and Drug Admnstraton. Avalable at https://wayback.archve- t.org/7993/20180125101447/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm473505.htm. 2015 Nov 18; Accessed: June 6, 2020.
Guideline, Thanacoody R, Caravati EM, Troutman B, Hojer J, Benson B, Hoppu K, et al. Position paper update: Whole bowel irrigation for gastrointestinal decontamination of overdose patients. Clin Toxicol (Phila). 2015 Jan. 53(1):5-12.
Opioid Overdose: Data Overview. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/drugoverdose/data/index.html. March 19, 2020; Accessed: June 6, 2020.
Porter R, O'Reilly H. Pulmonary hemorrhage: a rare complication of opioid overdose. Pediatr Emerg Care. 2011 Aug. 27(8):742-4.
Asher J. Schranz, MD, Aaron Fleischauer, PhD, [...], and David L. Rosen, MD, PhD, Trends in drug use-associated infective endocarditis and heart valve surgery, 2007 to 2017
Fine PG. Principles of effective pain management at the End of Life. [CME] 2006 [cited 2006 November]; Available from: http://www.medscape.com/viewprogram/6079
Christenson J, Etherington J, Grafstein E, et al: Early discharge of patients with presumed opioid overdose: development of a clinical prediction rule. Acad Emerg Med 7: 1110, 2000.
Willman MW, Liss DB, Schwarz ES, Mullins ME: Do heroin overdose patients require observation after receiving naloxone? Clin Toxicol (Phila) 55: 81, 2017.
Clemency BM,Eggleston W,Shaw EW,et al. Hospital observation upon reversal (HOUR) with naloxone: a prospective clinical prediction rule validation study.Acad Emerg Med 2018 Dec 28